Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States.

ABSTRACT:

Introduction

We estimate societal value of a disease-modifying Alzheimer's disease (AD) treatment that reduces progression by 30% in early stages.

Methods

Using the International Society for Pharmacoeconomics and Outcomes Research value flower as framework, we estimate gross societal value, that is, not including treatment cost, from avoided medical and social care costs, productivity and quality-adjusted life-years (QALY) gains for patients and caregivers, adjusting for severity of disease, value of financial insurance, and value of insurance for currently unafflicted adults with a Markov model.

Results

Predicted societal value from 2021 until 2041 is $2.62 trillion for the overall afflicted US population and $986 billion for the 2021 prevalent cohort or $134,418 per

SUBMITTER: Prados MJ 

PROVIDER: S-EPMC9303743 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature